

[illegible]

- Sub 02

10. (Amended) A method of producing an immunogenic peptide comprising the step of immunizing with a peptide having the amino acid sequence

-Cys-Ile-Thr-Gln-Tyr-Glu-Arg-Glu-Ser

or

-Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-Ser

thereof, obtained by substituting, deleting or inserting one or more amino acids in the amino acid sequence, provided that the three dimensional conformation of the peptide is maintained to elicit an immune response.

11. (Amended) ~~A kit~~ [Kit] for the diagnosis and/or the treatment of BSE and/or CJD and/or vCJD or TSE related diseases, containing an antibody according to claim 1 [any of the claims 1 to 6].

12. (Amended) ~~A pharmaceutical~~ [Pharmaceutical] composition, comprising an antibody according to claim 1 [any of the claims 1 to 6].

13. (Amended) ~~A hybridoma~~ [Hybridoma] cell line capable of producing [to produce] an antibody according to claim 1 [any of the claims 1 to 6].

15. (Amended) ~~An antibody~~ [Antibody] directed to the idiotype of an antibody according to claim 1 [any of the claims 1 to 6].

Respectfully submitted,



Michael L. Goldman
Registration No. 30,727

Date: May 23, 2000

NIXON PEABODY LLP
Clinton Square, P.O. Box 1051
Rochester, New York 14603
Telephone: (716) 263-1304
Facsimile: (716) 263-1600